Advertisement

Topics

Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results

17:19 EDT 14 Mar 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
RSV Phase 3 Prepare(TM) Trial Outcome De-risked by Successful Informational Analysis NanoFlu(TM) Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine John J. Trizzino Appointed Chief Business Officer and Chief...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...